An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Phase of Trial: Phase III
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Reslizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Teva Branded Pharmaceutical Products R&D
- 17 Apr 2017 Planned primary completion date changed from 31 Aug 2018 to 31 Aug 2017.
- 17 Apr 2017 Status changed from not yet recruiting to recruiting.
- 17 Feb 2017 New trial record